This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street

Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility. Early-stage innovation stocks can be hard on the nerves. Short-sellers frequently pile into these stocks ahead of major catalysts, driving the stock price down significantly. Worst of all, these trough periods can persist for years as companies develop key product candidates, pass through major regulatory hurdles, and prepare to enter the market. However, these stocks c ...